Dermsquared Scheduled Maintenance, Thursday Feb 29, 6:30am to 8:30am EST

2023 Fall Clinical Virtual Grand Rounds

2024 Virtual Grand Rounds Session 1: January 31, 2024 - WCH24 Your Questions Answered

About

Fall Clinical Virtual Grand Rounds consist of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:

Wednesday, January 31, 2024

8 PM ET / 5 PM PT

Winter Clinical Dermatology Conference-Hawaii (WCH24): Your Questions Answered

This activity is supported by educational grants from Genentech, a member of the Roche Group, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals.

Availability

In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:

Release Date:

February 1, 2024

Expiration Date:

February 1, 2025

Learning Objectives

At the completion of this activity, participants should be better able to:

  • Discuss the treatment of psoriasis and related disorders with evolving therapies

  • Recognize the various therapies available for acne and their role in clinical practice

  • Translate the role of therapies for eczema in clinical practice

  • Describe the modalities for diagnosing and managing skin cancer

  • Identify optimal patients for the use of fillers and botulinum

  • Describe strategies to prepare and administer fillers and botulinum

  • Illustrate strategies to manage dermatologic conditions effectively in clinical practice

Intended Audience
This activity has been designed for dermatologists, dermatology physician assistants, dermatology nurse practitioners, and other providers involved in the care of patients.
Faculty
April
April Armstrong, MD, MPH

Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA

James
James Del Rosso, DO

Adjunct Clinical Professor, Dermatology
Touro University Nevada
Henderson, NV

Dee Anna
Dee Anna Glaser, MD

Professor and Vice-Chairman 
Department of Dermatology
Saint Louis University School of Medicine
St. Louis, MO

Mark
Mark Lebwohl, MD

Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY

Darrell
Darrell Rigel, MD, MS

Clinical Professor of Dermatology 
Director, Melanoma Surveillance Clinic 
Mount Sinai Icahn School of Medicine, New York, NY 
Adjunct Professor, UT Southwestern Medical School 
Consultant Dermatologist, Cooper Clinic, Dallas, TX

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Institute for Continuing Healthcare Education and CMEsquared. The Institute is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

The Institute for Continuing Healthcare Education designates this live and enduring activity for a maximum of 1 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures & Disclaimers

CONFLICTS OF INTEREST/DISCLOSURES

In accordance with the ACCME Standards for Commercial Support, balance, independence, objectivity, and scientific rigor are ensured in all CME activities. This requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with any ineligible companies. In addition, the content of this material has been approved by an independent peer reviewer. 

Disclosures are as follows:

April W. Armstrong, MD, MPH

Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen 

Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel 

James Q. Del Rosso, DO

Grant/Research Support: Aclaris, Amgen, Anaptys Bio, Arcutis, Athenex, Bausch (Ortho), Biorasi, Botanix, Brickell, Cara Therapeutics, Cassiopea, Dermavant, EPI Health, Galderma, Genentech, Incyte, Janssen, LEO, Lilly, Novan, Pfizer, Ralexar, Sanofi Genzyme Regeneron, Sol-Gel, SUN, Vyne

Consultant: Abbvie, Aclaris, Almirall, Amgen, Arcuits, Bausch (Ortho), Biofrontera, Biopharmx, Blue Creek, BMS, Cassiopea, Dermata, Dermavant, Encore, EPI Health, Evoummune, Ferndale, Galderma, Incyte, Jem Health, LEO, La Roche Posay, Lilly, MC2, Novan, Pfizer, Sanofi Genzyme Regeneron, Sente, Sol-Gel, Sonoma, SUN, UCB, Verrica, Vyne

Speakers’ Bureau or Honoraria: Abbvie, Aclaris, Almiral, Amgen, Bausch (Ortho), Biofrontera, Encore, EPI Health Ferndale, Galderma, Genentech, Jem Health, LEO, Lilly, Pfizer, Sanofi Genzyme Regeneron, SUN, UCB, Verrica, Vyne

Dee Anna Glaser, MD

Advisory Board: Allergan, Biersdorf, Candesant, Neutrofol, Primus

Speaker's Bureau: Allergan

Ownership Interest: Candesant

Mark Lebwohl, MD

Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.

Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.

Darrell S. Rigel, MD, MS

Grant/Research Support: Castle Biosciences, SciBASE

Consultant: DermTech, Ferndale Laboratories, Inc., SciBase, VYNE Therapeutics 

Speakers’ Bureau or Honoraria: Castle Biosciences

Advisory Board: Almirall, Beiersdorf, Inc., Castle Biosciences, Johnson and Johnson 

The planners have disclosed that they have no relevant financial relationships with any Ineligible Company in the past 24 months.  

The Institute discloses that all relevant conflicts have been satisfactorily mitigated.


Dermsquared

The leading solutions platform for dermatology professionals to elevate patient care.

Contact Us

Support

Subscribe now

Enter your email to get the latest updates.

© 2024 dermsquared | All Rights Reserved